Clinical Trial Update: NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating neoadjuvant Sacituzumab Govitecan plus Pembrolizumab versus standard-of-care chemotherapy in clinical stage II-III triple-negative earl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer, Triple-negative Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING